Market capitalization | KRW6.99t |
Enterprise Value | KRW6.87t |
P/E (TTM) P/E ratio | 27.81 |
EV/FCF (TTM) EV/FCF | 66.94 |
EV/Sales (TTM) EV/Sales | 11.88 |
P/S ratio (TTM) P/S ratio | 12.09 |
P/B ratio (TTM) P/B ratio | 12.31 |
Revenue growth (TTM) Revenue growth | 41.64% |
Revenue (TTM) Revenue | KRW578.00b |
As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.
11 Analysts have issued a SK Biopharmaceuticals forecast:
11 Analysts have issued a SK Biopharmaceuticals forecast:
Mar '25 |
+/-
%
|
||
Revenue | 577,999 577,999 |
42%
42%
|
|
Gross Profit | 523,340 523,340 |
48%
48%
|
|
EBITDA | 129,408 129,408 |
1,040%
1,040%
|
EBIT (Operating Income) EBIT | 111,716 111,716 |
2,352%
2,352%
|
Net Profit | 251,211 251,211 |
1,521%
1,521%
|
In millions KRW.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
SK Biopharmaceuticals Co., Ltd. engages in the research and development of new drugs and antibiotics. It mainly develops new drugs for central nervous system disorders, and brain tumors. The company was founded in 1993 and is headquartered in Seongnam-si, South Korea.
Head office | South Korea |
CEO | Dong-Hoon Lee |
Employees | 265 |
Founded | 1993 |
Website | www.skbp.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.